Lung Cancer News

Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results

Lung Cancer: Timing May Affect EGFR mutation-related ctDNA Test Results

Timing might affect the results of an EGFR mutation-frequency circulating tumor DNA (ctDNA) test among patients with advanced NSCLC.

Proton Therapy Trial Among Patients With Stage I NSCLC

Proton Therapy Trial Among Patients With Stage I NSCLC

Researchers are evaluating whether hypoIGRT is an effective treatment strategy for patients with stage I NSCLC who are not candidates for surgery.

Phase 3 Trial of SPECT/CT Imaging for Lung Cancer

Phase 3 Trial of SPECT/CT Imaging for Lung Cancer

Researchers are attempting to determine whether SPECT/CT imaging is non-inferior to PET/CT imaging for lung cancer.

Clinician Communication, Perceived Burden Critical for Adherence to Oral Chemotherapy

Clinician Communication, Perceived Burden Critical for Adherence to Oral Chemotherapy

Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.

Nivolumab Associated With Durable Long-term Responses in Lung Cancer

Nivolumab Associated With Durable Long-term Responses in Lung Cancer

Immune checkpoint inhibition with nivolumab is associated with durable clinical responses and a 16% 5-year survival rate among heavily pretreated patients with advanced NSCLC.

FDA Approves Osimertinib for EGFR T790M Mutation-positive NSCLC

FDA Approves Osimertinib for EGFR T790M Mutation-positive NSCLC

The US Food and Drug Administration approved osimertinib for the treatment of EGFR T790M mutation-positive NSCLC.

ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer

ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer

In an indirect comparison, brigatinib appeared to have greater efficacy than alectinib or ceritinib in ALK+ non-small cell lung cancer.

Racial Disparities Persist in Treatment and Outcomes of Early Stage NSCLC

Racial Disparities Persist in Treatment and Outcomes of Early Stage NSCLC

Racial disparities in treatment and outcomes persist among patients diagnosed with NSCLC in spite of advances in curative therapies.

SBRT for Elderly Patients With Unresectable Lung Cancer

SBRT for Elderly Patients With Unresectable Lung Cancer

SBRT may be an effective strategy for elderly patients with unresectable lung cancer.

Reirradiation of Thoracic Cancers Provides Disease Control and Minimal Toxicity

Reirradiation of Thoracic Cancers Provides Disease Control and Minimal Toxicity

Definitive reirradiation of thoracic cancers with IMPT can provide durable local control with minimal toxicity and can extend survival.

Circulating Tumor Cell Monitoring Offers Early Prediction of Recurrent NSCLC

Circulating Tumor Cell Monitoring Offers Early Prediction of Recurrent NSCLC

Post-radiotherapy samples in 20 of 22 recurrences revealed that 15 of these patients (75%) had an increase in CTC counts.

Combining Radiotherapy and Immunotherapy: Adverse Events in Lung Cancer

Combining Radiotherapy and Immunotherapy: Adverse Events in Lung Cancer

In an analysis of metastatic lung cancer treated with thoracic radiotherapy and immunotherapy, 3 patients had severe toxicity.

Genetic Variations and Therapy Resistance in EGFR-mutant NSCLC

Genetic Variations and Therapy Resistance in EGFR-mutant NSCLC

Resistance to EGFR-targeted therapies may not be permanent; a single biopsy is insufficient for fully understanding the nature of therapy resistance.

Hodgkin Lymphoma Survivors at Risk for Second Cancers

Hodgkin Lymphoma Survivors at Risk for Second Cancers

Survivors with a family history of colorectal, breast, and lung cancer were at a significantly higher risk of similar second cancers.

Low Response Rate With Multikinase Inhibitors in RET-rearranged NSCLC

Low Response Rate With Multikinase Inhibitors in RET-rearranged NSCLC

Currently-available multikinase inhibitors that target RET kinase had limited activity in patients with non-small cell lung cancer (NSCLC) with RET rearrangements.

Evaluating Concordance Among PD-L1 Assays in Non-small Cell Lung Cancer

Evaluating Concordance Among PD-L1 Assays in Non-small Cell Lung Cancer

Dako/Agilent 28-8, Dako/Agilent 22c3, and Leica Bond E1L3N yield similar results for PD-L1 expression testing in tumor cells, though Ventana SP142 is a less effective assay.

Adjuvant Statins Provide No Benefit in SCLC

Adjuvant Statins Provide No Benefit in SCLC

The addition of pravastatin to the first-line standard of care failed to provide benefit for patients with small-cell lung cancer (SCLC).

Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Efficacy of Osimertinib in Advanced T790M-positive NSCLC

Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with non-small cell lung cancer (NSCLC).

NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib

NSCLC: No Overall Survival Difference Between Afatinib and Gefitinib

No significant difference in overall survival between afatinib and gefitinib among patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC).

Lung Cancer Screening Rates Remain Low Despite USPSTF Recommendations

Lung Cancer Screening Rates Remain Low Despite USPSTF Recommendations

Only 262,700 of the eligible 6.8 million smokers or ex-smokers underwent LDCT in 2015.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters